Buy Oxlumo (lumasiran) Online For Sale

Description

Oxlumo (lumasiran) is a new medication for treating primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes a build-up of oxalate in the body. This condition can lead to kidney stones, kidney damage, and other serious health problems.

Oxlumo is an RNA-based therapy that targets the production of glycolate oxidase, an enzyme that leads to the accumulation of oxalate in individuals with PH1. By reducing the production of glycolate oxidase, Oxlumo can reduce the levels of oxalate in the body and prevent damage to the kidneys and other organs.

Oxlumo was approved by the US Food and Drug Administration (FDA) in November 2020 and is the first medication specifically indicated for the treatment of PH1. Oxlumo is administered via subcutaneous injection once a month.

Clinical trials have demonstrated the effectiveness of Oxlumo in treating PH1. A Phase 3 trial showed that patients taking Oxlumo experienced a significant reduction in urinary oxalate levels compared to those on placebo. Participants in the trial also had fewer kidney stones and less kidney damage.

Oxlumo has some potential side effects, such as injection site reactions, abdominal pain, and nausea. In addition, the medication can interact with other drugs, such as antibiotics and anticoagulants, and should be used with caution in patients with liver or kidney problems.

Despite these risks, Oxlumo is a major breakthrough in the treatment of PH1. Prior to its approval, there were no available treatments to prevent the build-up of oxalate in the body, and patients with PH1 often required dialysis or kidney transplantation. Oxlumo now offers a new hope to these patients by reducing the levels of oxalate in the body and preventing the progression of kidney damage.

In conclusion, Oxlumo is a new RNA-based therapy designed to treat primary hyperoxaluria type 1 by reducing the production of glycolate oxidase, the enzyme responsible for the accumulation of oxalate in individuals with PH1. The medication has been shown to be effective in reducing urinary oxalate levels and preventing kidney stones and damage in clinical trials. While there are potential side effects and drug interactions, Oxlumo is a significant breakthrough in the treatment of PH1, providing hope for patients suffering from this rare and debilitating condition.